Literature DB >> 32805305

Construction of prokaryotic strand-specific primary-transcripts saturated RNASeq library by controlled heat magnesium-dependent mRNA degradation.

Kirill S Mironov1, Maria Shumskaya2, Dmitry A Los3.   

Abstract

The main limiting factors for RNA-Seq analysis are quality and quantity of the isolated mRNA. In prokaryotes, the proportion of messenger RNA to total RNA is rather low. Therefore, the main strategy of library preparation for sequencing is mRNA enrichment. Ribosomal and transfer RNAs, both monophosphorylated at the 5'-ends, are the major fractions of total RNA, while the bulk of primary transcripts is triphosphorylated at the 5'-teminus. Due to its low molecular weight, transfer RNA could be easily removed by a quick precipitation in LiCl solution. Ribosomal RNA may be degraded enzymatically by 5'-end terminal exonuclease XRN-1. These steps allow enriching samples in mRNA during the first stages of RNA-Seq library preparation. The desired level of fragmentation of enriched mRNA necessary for the 2nd generation sequencing can be controlled by the duration of incubation at elevated temperatures in the presence of Mg2+-ions. Here, we describe a simple protocol for construction of the primary prokaryotic mRNA-saturated library without long depletion procedures.
Copyright © 2020 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.

Entities:  

Keywords:  Primary transcripts; RNASeq; XRN-1; cDNA library preparation; mRNA; rRNA depletion

Mesh:

Substances:

Year:  2020        PMID: 32805305     DOI: 10.1016/j.biochi.2020.08.001

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  1 in total

1.  Evaluation of Advantages of Lithium Chloride as a Precipitating Agent in RNA Isolation from Frozen Vein Segments.

Authors:  V A Korolenya; K A Gavrilov; K S Sevost'ianova; A I Shevela; M L Filipenko; M A Smetanina
Journal:  Bull Exp Biol Med       Date:  2022-07-19       Impact factor: 0.737

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.